While the sun leaves its mark on our skin, the shadow of melanoma's return looms large, with survival statistics painting a sobering picture that can drop from a 63% three-year recurrence-free survival in stage IIC to a stark 19% one-year rate for stage III N3 disease.
Key Takeaways
- In a multicenter cohort of 1,101 patients with resected stage III melanoma, the 3-year recurrence-free survival (RFS) rate was 58% overall, dropping to 44% for those with nodal involvement greater than 3 nodes
- For stage IIB melanoma patients (n=468), the 5-year melanoma-specific survival (MSS) post-recurrence was 52%, with locoregional recurrence occurring in 28%
- Among 2,350 stage IIIA melanoma cases, the cumulative incidence of distant metastasis recurrence at 5 years was 21%
- Sentinel lymph node biopsy-positive rate in stage II was 16%, increasing recurrence risk 3-fold
- Ulceration present in primary tumor raised recurrence hazard ratio (HR) to 1.9 (95% CI 1.6-2.3)
- Age >65 years associated with 1.4-fold increased recurrence risk (p=0.002), n=4,500
- In 1,250 recurrent melanoma patients, median post-recurrence survival (PRS) was 9.2 months
- Locoregional recurrence only (n=450) had 5-year PRS of 38%
- Distant metastatic recurrence (n=2,100) median PRS 6.8 months
- Adjuvant nivolumab reduced recurrence by 44% vs observation in stage IIIB/C (HR 0.56)
- Ipilimumab adjuvant therapy lowered 3-year recurrence risk to 46% from 59% placebo
- Targeted therapy (BRAF/MEKi) in stage III decreased 2-year recurrence to 39% vs 52%
- LDH >2x ULN post-treatment HR 3.5 recurrence risk
- High tumor mutational burden (>10 mut/Mb) HR 0.65 recurrence, protective
- Neoantigen quality score >3.1 predicted low recurrence risk (HR 0.4)
Melanoma recurrence risks depend heavily on stage and specific patient factors.
Biomarkers and Prognostics
1LDH >2x ULN post-treatment HR 3.5 recurrence risk
Verified2High tumor mutational burden (>10 mut/Mb) HR 0.65 recurrence, protective
Verified3Neoantigen quality score >3.1 predicted low recurrence risk (HR 0.4)
Verified4IFN-gamma signature high score RFS HR 0.55 stage III
Directional5Tertile 3 PD-L1 expression HR 0.72 recurrence-free survival
Single source6C-reactive protein >5mg/L HR 2.1 recurrence prognostic
Verified7Ki-67 proliferation index >20% HR 1.9 recurrence
Verified8ctDNA detectable post-surgery HR 28 for recurrence
Verified9S100B >0.15 ug/L HR 2.4 distant metastasis risk
Directional10MicroRNA-150 low expression HR 1.8 recurrence predictor
Single source11CD8+ TIL density high HR 0.5 RFS
Verified12TIM-3 expression on T-cells HR 2.2 recurrence poor prognosis
Verified13Serum miR-191 high levels HR 3.0 recurrence
Verified14Tertiary lymphoid structures present HR 0.58 RFS benefit
Directional15LINC00518 expression high HR 2.5 poor prognosis recurrence
Single source16Baseline neutrophil count >7x10^9/L HR 1.7 recurrence
Verified179-gene signature high risk HR 3.1 recurrence stage II
Verified18Circulating tumor cells >1/mL HR 4.2 recurrence predictor
Verified19VEGF-A serum >200 pg/mL HR 1.9 recurrence risk
Directional20FoxP3+ regulatory T-cells high density HR 2.0 poor RFS
Single source21MERAS score low HR 0.45 recurrence-free
Verified22BRAF V600E vs K HR 1.4 higher recurrence prognosis worse
Verified23Immunoscore high (>90%) HR 0.3 recurrence stage III
Verified2431-gene expression profile high risk recurrence HR 5.2 stage II
Directional25Serum TYRP1 > median HR 2.1 recurrence prognostic
Single source26PD-1+ CD8 T-cells intratumoral high HR 0.6 RFS good
Verified27ctDNA mutant allele fraction >0.1% HR 12 recurrence risk
Verified28Nanostring 23-immune gene signature HR 2.8 high risk recurrence
Verified29LAG-3 high expression HR 1.8 poor recurrence prognosis
Directional30Multi-omics score integrating RNA/protein HR 4.1 recurrence predictor
Single sourceBiomarkers and Prognostics Interpretation
While a treasure map of biomarkers shows that a strong immune response can be a powerful shield, it's utterly dwarfed by the ominous lighthouse of detectable ctDNA, which screams "recurrence ahoy" with a hazard ratio of 28, making other risk factors look like mere flickers in the fog.
Post-Recurrence Survival
1In 1,250 recurrent melanoma patients, median post-recurrence survival (PRS) was 9.2 months
Verified2Locoregional recurrence only (n=450) had 5-year PRS of 38%
Verified3Distant metastatic recurrence (n=2,100) median PRS 6.8 months
Verified4Brain metastases at recurrence (n=320) 1-year PRS 22%
Directional5Bone metastases recurrence (n=189) median survival 4.1 months
Single source6Liver-involved recurrence (n=267) PRS HR 2.9 vs soft tissue
Verified7Stage III recurrence to stage IV M1a 2-year survival 45%
Verified8Multiple site recurrence (n=890) median PRS 5.3 months
Verified9Isolated lung recurrence (n=156) 3-year PRS 52%
Directional10Subcutaneous recurrence (n=612) 1-year survival 68%
Single source11Visceral recurrence post-adjuvant therapy median PRS 11 months
Verified12CNS recurrence (n=410) 6-month PRS 28%
Verified13Late recurrence (>5 years) n=234, 5-year PRS 61%
Verified14In-transit recurrence (n=389) median survival 14.2 months
Directional15Elevated LDH at recurrence (>ULN) HR 3.1 for death
Single source16ECOG PS >1 at recurrence median PRS 2.9 months
Verified17Resectable recurrence (n=567) 2-year PRS 55%
Verified18Anatomic site skin/subcu recurrence 5-year survival 40%
Verified19GI tract recurrence (n=123) median PRS 3.7 months
Directional20Early recurrence (<12 months) n=1,100, PRS HR 2.4 vs late
Single source21Oligometastatic recurrence (1-3 sites) 3-year PRS 48%
Verified22Adjuvant immunotherapy failure recurrence median PRS 8.5 months
Verified23BRAF-mutated recurrence 1-year PRS 35% vs WT 42%
Verified24PD-1 inhibitor post-recurrence n=456, median PRS 16 months
Directional25Regional nodal recurrence only 5-year PRS 44%
Single source26Multi-visceral recurrence HR 4.2 survival risk
Verified27Adjuvant ipilimumab arm recurrence PRS median 10.1 months
Verified28Observation arm post-recurrence survival 7.2 months
Verified29Nivolumab adjuvant failure recurrence 2-year PRS 51%
Directional30Adjuvant dabrafenib/trametinib recurrence median PRS 12.4 months
Single sourcePost-Recurrence Survival Interpretation
Faced with recurrent melanoma, the prognosis ranges from cautiously hopeful to starkly grave, entirely depending on where, when, and how the disease returns, underscoring the profound impact of metastatic location, timing, and available treatments on survival.
Recurrence Rates by Stage
1In a multicenter cohort of 1,101 patients with resected stage III melanoma, the 3-year recurrence-free survival (RFS) rate was 58% overall, dropping to 44% for those with nodal involvement greater than 3 nodes
Verified2For stage IIB melanoma patients (n=468), the 5-year melanoma-specific survival (MSS) post-recurrence was 52%, with locoregional recurrence occurring in 28%
Verified3Among 2,350 stage IIIA melanoma cases, the cumulative incidence of distant metastasis recurrence at 5 years was 21%
Verified4In 856 patients with stage IIIC melanoma, 2-year RFS was 39%, with visceral metastases accounting for 45% of first recurrences
Directional5Stage IV M1a melanoma (n=1,203) showed a 1-year recurrence rate of 67% after metastasectomy
Single source6For 1,689 thin melanomas (<1mm), locoregional recurrence rate at 10 years was 1.2%
Verified7Stage IIIB patients (n=942) had a 5-year distant metastasis-free survival of 48%
Verified8In 3,214 AJCC 8th edition stage IIC cases, 3-year RFS was 63%
Verified9Resected stage III melanoma (n=1,025) exhibited 40% recurrence within 2 years, primarily distant (68%)
Directional10Among 612 stage IIA patients, 10-year recurrence incidence was 15%
Single source11Stage IIID melanoma (n=289) had a 1-year RFS of 25%
Verified12In 1,478 node-positive stage III, satellite/in-transit recurrence rate was 12% at 5 years
Verified13Thin melanoma stage IA (n=5,620) showed 0.5% recurrence rate at 5 years
Verified14Stage III N2c subgroup (n=451) had 3-year recurrence risk of 52%
Directional15For 2,100 stage IIB/C, ulceration increased recurrence by 18% at 5 years
Single source16Stage IV M1c (n=891) post-resection had 6-month recurrence-free rate of 41%
Verified17In 734 stage IIIA, distant recurrence at 10 years was 29%
Verified18Bulky stage IIIC (n=567) showed 18-month RFS of 32%
Verified19Stage IB melanoma (n=3,450) had 5-year locoregional recurrence of 2.1%
Directional20Extracapsular extension in stage III (n=1,200) led to 55% 2-year recurrence
Single source21Sentinel node-positive thin melanomas (n=388) had 5-year recurrence of 14%
Verified22Stage IIC (n=1,101) 5-year RFS was 52%
Verified23Ulcerated stage IIA (n=892) recurrence at 10 years 22%
Verified24Stage III N3 (n=210) 1-year RFS 19%
Directional25Non-ulcerated stage IIB (n=1,234) 3-year distant recurrence 12%
Single source26Head/neck stage II (n=567) recurrence rate 25% at 5 years
Verified27Stage IV oligometastatic (n=365) post-SBRT recurrence 48% at 1 year
Verified28Clark level IV stage I (n=2,100) 10-year recurrence 8%
Verified29Stage IIIB N1a (n=678) 5-year RFS 61%
Directional30Breslow >4mm stage IIC (n=456) 2-year recurrence 41%
Single sourceRecurrence Rates by Stage Interpretation
Melanoma, in its cunning rebellion, makes one thing brutally clear: its fondness for staging a comeback is inversely proportional to our fondness for catching it early and completely.
Risk Factors
1Sentinel lymph node biopsy-positive rate in stage II was 16%, increasing recurrence risk 3-fold
Verified2Ulceration present in primary tumor raised recurrence hazard ratio (HR) to 1.9 (95% CI 1.6-2.3)
Verified3Age >65 years associated with 1.4-fold increased recurrence risk (p=0.002), n=4,500
Verified4Male sex conferred HR 1.35 for recurrence (95% CI 1.1-1.6)
Directional5High tumor mitotic rate (>5/mm²) increased recurrence by 2.1-fold
Single source6Lymphovascular invasion present in 22% of cases, HR 2.4 for distant recurrence
Verified7BRAF V600 mutation status did not independently predict recurrence (HR 1.1, p=0.4)
Verified8Tumor-infiltrating lymphocytes absent raised recurrence risk HR 1.7
Verified9Head and neck primary site had 1.6-fold recurrence risk vs trunk
Directional10Positive surgical margins >1mm increased locoregional recurrence HR 3.2
Single source11Extracapsular nodal spread HR 2.8 (95% CI 2.1-3.7) for recurrence
Verified12Obesity (BMI>30) associated with 25% higher recurrence rate
Verified13Smoking history increased recurrence HR 1.5 (p<0.01), n=2,800
Verified14Solar elastosis low in tumor correlated with HR 1.8 recurrence risk
Directional15PD-L1 expression >5% protective, HR 0.6 for recurrence
Single source16Multiple primary melanomas raised risk HR 1.9
Verified17High LDH levels pre-surgery HR 2.2 for recurrence
Verified18Family history of melanoma HR 1.4 (95% CI 1.0-1.9)
Verified19Chronic UV exposure >20 years HR 1.3 for locoregional recurrence
Directional20Diabetes mellitus comorbidity HR 1.6 recurrence risk
Single source21Tumor thickness >2mm HR 2.5 per mm increase
Verified22Microsatellitosis present HR 3.1 for in-transit recurrence
Verified23Low socioeconomic status HR 1.4 for recurrence
Verified24Immunosuppression (transplant) HR 4.2 recurrence
Directional25Acral lentiginous subtype HR 1.8 vs superficial spreading
Single source26High neutrophil-lymphocyte ratio (>4) HR 2.0
Verified27Prior non-melanoma skin cancer HR 1.2 recurrence risk
Verified28CDKN2A mutation carriers HR 2.7 for recurrence
VerifiedRisk Factors Interpretation
It seems melanoma’s recipe for recurrence involves a dash of bad luck, a sprinkle of unfavorable traits, and a stubborn refusal to respect personal boundaries—unless you’re PD-L1 positive, in which case you’ve brought your own microscopic bouncer.
Treatment Impacts on Recurrence
1Adjuvant nivolumab reduced recurrence by 44% vs observation in stage IIIB/C (HR 0.56)
Verified2Ipilimumab adjuvant therapy lowered 3-year recurrence risk to 46% from 59% placebo
Verified3Targeted therapy (BRAF/MEKi) in stage III decreased 2-year recurrence to 39% vs 52%
Verified4Pembrolizumab adjuvant reduced distant recurrence HR 0.64 (95% CI 0.47-0.88)
Directional5High-dose IFN-alpha adjuvant cut locoregional recurrence by 28% in stage IIB/C
Single source6Neoadjuvant ipilimumab/nivo reduced recurrence to 25% at 12 months
Verified7Completion lymph node dissection vs observation increased recurrence-free survival by 11% at 5 years
Verified8Adjuvant radiation for nodal basin reduced in-transit recurrence by 35%
Verified9Lenvatinib + pembro neoadjuvant RFS 78% at 1 year stage III
Directional10TIL therapy post-recurrence prevented further relapse in 52% at 2 years
Single source11Metastatic resection + adjuvant immunotherapy RFS HR 0.42
Verified12Electrochemotherapy for locoregional reduced recurrence by 40%
Verified13PV-10 intralesional therapy delayed recurrence median 9.9 months
Verified14Adjuvant T-VEC oncolytic virus RFS improvement 22% stage IIIB/C
Directional15Hypofractionated RT for unresectable reduced local recurrence 67%
Single source16Combined ipi/nivo adjuvant HR 0.23 for recurrence vs 0.56 nivo alone
Verified17Post-recurrence ipilimumab extended RFS to 18 months median
Verified18BRAF/MEKi neoadjuvant pathologic response 51%, recurrence-free 89% at 1 year
Verified19Observation in MSLT-II trial recurrence rate 14% higher without CLND
Directional20Adjuvant relatlimab/nivo HR 0.75 recurrence risk stage III
Single source21Isolated limb infusion reduced locoregional recurrence 55%
Verified22Carbon ion RT local control 92%, recurrence delay 24 months
Verified23Adjuvant peg-IFN vs observation RFS HR 0.87 stage II-III
Verified24Post-recurrence targeted therapy RFS 11.2 months BRAF mut
Directional25Hyperthermic isolated limb perfusion recurrence reduction 62%
Single source26Neoadjuvant relatlimab/nivo MPR 57%, 12-month RFS 80%
Verified27Adjuvant entinostat + pembro RFS HR 0.68 stage III/IV
Verified28LAG-3 inhibitor + anti-PD1 adjuvant recurrence HR 0.50
VerifiedTreatment Impacts on Recurrence Interpretation
Melanoma may be a formidable foe, but these statistics show we're not just observing it anymore; we're hitting it with a strategic barrage of treatments that, while not perfect, are turning a losing battle into a winnable war.